Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × pembrolizumab × Plasma cell × Clear all

Phase

Phase 2 10 Phase 1 6 Phase 1/2 5 Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 88 Gastrointestinal 31 Genitourinary 27 Head & Neck 19 Gynecologic 16 Dermatologic 16 Breast 16 Tumor-Agnostic 4 Sarcoma 3 CNS 3 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 NET 1 Lymphoid 1 Endocrine 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 143 Bortezomib 83 Lenalidomide 78 Melphalan 41 Thalidomide 39 daratumumab 36 Cyclophosphamide 32 pomalidomide 30 Calcium Dobesilate 25 carfilzomib 20 Prednisone 18 Filgrastim 13 Doxorubicin 13 elotuzumab 11 ixazomib 10 isatuximab 9 Vincristine 9 Granulocyte Colony-Stimulating Factor 9 dexamethasone acetate 8 belantamab mafodotin 8 Zoledronic Acid 8 Peripheral Blood Stem Cell Transplantation 8 Epoetin Alfa 6 selinexor 5 fludarabine 5 Carmustine 5 dexamethasone 21-phosphate 4 auricularum 4 Radiotherapy 4 Interferon-alpha 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02576977 2021-10-08

KEYNOTE 183

Merck Sharp & Dohme LLC

Phase 3 Terminated

251 enrolled 17 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡